

Georgia Statistics

PCSK9 Inhibitors



About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Georgia from January 2017 through December 2017.

Key Georgia Findings



Rejection Rate:

31%



Appeals Rate:

25%



Final Rejections:

3,180

Of health plans that received at least 200 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

- Anthem **80%**
- Georgia State Health Benefit Plan **54%**
- Tricare Military Health SVC SYS **53%**
- Express Scripts **49%**

The following had **the lowest rates of rejection:**

- Cigna Healthcare **18%**
- Humana Health Plan **13%**



The following table details claims data for the Georgia managed care organizations that received at least 200 claims for PCSK9 inhibitors.

Managed Care Organization	Rejection %	Total Claims	Rejections
Anthem	80%	305	245
Georgia State Health Benefit Plan	54%	271	146
Tricare Military Health SVC SYS	53%	223	119
Express Scripts	49%	473	234
CVS Health	39%	870	336
Wellcare Management Group	33%	214	70
United Health Group	30%	2,217	673
Aetna	20%	1,202	235
Cigna Healthcare	18%	506	92
Humana Health Plan	13%	2,135	276

Data source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017.



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

